全国垂询热线
020-84128820


新闻资讯

联系我们

广州市雨纯生物科技有限公司
全国垂询热线:020-84128820
传真:020-84128836
地址:广州市增城中新镇福和坪中南路151号

Healthy China rises to national strategy Pharmaceutical companies need to tap new energy
专栏:Industry News
发布日期:2015-11-30
阅读量:2033
作者:佚名
收藏:
  [China Pharmaceutical Network Market Analysis] Recently, the "Proposal of the Central Committee of the Communist Party of China on Formulating the Thirteenth Five-Year Plan for National Economic an...
   [China Pharmaceutical Network Market Analysis] Recently, the "Proposal of the Central Committee of the Communist Party of China on Formulating the Thirteenth Five-Year Plan for National Economic and Social Development" was released, in which "Healthy China" rose to the national development strategy. Zhang Guimin, chairman and general manager of Lunan Pharmaceutical Group, said in an interview that in the next five years, China will step into a decisive stage of building a well-off society in an all-round way and achieving the goal of the first hundred years of struggle in the "two hundred years" struggle.

       In the “13th Five-Year Plan” proposal, “Healthy China” has risen to the national strategy. The core content also includes improving the basic drug system, improving the drug supply guarantee mechanism, rationalizing drug prices, and increasing the free supply of special drugs such as AIDS prevention and treatment. Improve the quality of medicines and ensure the safety of medications.

Zhang Guimin said that at this important historical juncture, the Party Central Committee put forward five development concepts of "innovation, coordination, green, openness, and sharing". Among them, innovation is in the first place and is at the core of the overall development of the country. This has great and far-reaching guiding significance for us to better adapt to the new trends of economic and social development, seize new opportunities, resolve new contradictions, and effectively respond to increasingly fierce international competition. The picture shows Zhang Guimin, chairman and general manager of Lunan Pharmaceutical Group.

Building a well-off society in an all-round way is the biggest bright spot

      In the face of the slowdown in the country's economic growth, for pharmaceutical companies, how to tap the new energy of the development of the pharmaceutical industry?

       Zhang Guimin said that the comprehensive construction of a well-off society will be the biggest highlight of this "Proposal". "A comprehensive well-off society is a goal of both quantitative and qualitative, with rich connotations covering economic, political, cultural, social, ecological civilization and other fields. The overall goal: sustained and healthy economic development, continuous expansion of people's democracy, markedly enhanced cultural soft power, comprehensive improvement of people's living standards, and significant progress in resource-saving and environment-friendly society construction are all important contents for building a well-off society in an all-round way. It’s the goal we work hard for.”

       Zhang Guimin said that the "Proposal" upgraded "Healthy China" to a new strategic level. As an innovative pharmaceutical company, Lunan Pharmaceutical Group has always built innovation-driven, resource-saving, environment-friendly and safety-guaranteed enterprises. aims. In the future, Lunan Pharmaceutical Group will make efforts to improve its innovation capabilities, improve product quality, and enhance its sustainable development capabilities, and make greater contributions to the overall goal of building a well-off society in an all-round way.

      Accelerating the achievements of scientific and technological innovation can help alleviate the "expensive medical treatment"

Zhang Guimin believes that deepening the reform of pharmaceutical production and circulation is a long-term task for the improvement of the drug supply guarantee mechanism mentioned in the "Proposal" and the rationalization of drug prices. The state is promoting pharmaceutical enterprises to improve their independent innovation capabilities and optimize the upgrading of the pharmaceutical industry structure. In terms of positive promotion measures, China's pharmaceutical R&D level has been continuously improved. By reforming innovative drugs and medical device evaluation systems and other policy measures, we have eliminated backward production capacity and encouraged enterprises to independently innovate in order to ensure the healthy development of China's pharmaceutical industry. the way.

Zhang Guimin said that rationalizing the price of medicines is the implementation of the decision of the Third Plenary Session of the 18th CPC Central Committee. "We must actively and steadily promote market-oriented reforms from breadth and depth, greatly reduce the direct allocation of resources by the government, and promote the allocation of resources according to the market. The actual actions of the spirit of rules, market prices, market competition to maximize benefits and optimize efficiency. The common people are faced with the problem of “difficulty in seeing a doctor” and “expensive medical treatment”. There are some families who even “poor due to illness and return to poverty due to illness”. Behind this phenomenon is the unreasonable allocation of medical resources and the low financial input. With the advancement of science and technology and the development of the times, these phenomena have been improved and alleviated. In the short-term, through centralized bidding and “second bargaining”, lowering drug prices can alleviate the phenomenon of insufficient financial investment and “expensive medical treatment”, but the symptoms are not cured. Importing the original research drug to raise the price for the pursuit of profiteering is because it has a monopoly position in the pharmaceutical market in China. In the long run, it is necessary to support China's pharmaceutical enterprises to improve their innovation capabilities and improve the competitiveness of national pharmaceutical products, in order to break this monopoly, and to industrialize and market the achievements of scientific and technological innovation as soon as possible by developing localized and cheaper market competition entities. Large-scale, so that the price of high drug prices can really be lowered, in order to solve the problem of solving the problem of "expensive medical treatment" for ordinary people.

      In terms of improving the quality of medicines and ensuring the safety of medicines, Zhang Guimin said that the plan made detailed recommendations on “in-depth implementation of the innovation-driven development strategy”, pointing out that “to play the leading role of technological innovation in comprehensive innovation, strengthen basic research, and strengthen original innovation, Integrate innovation and introduction, digestion, absorption and innovation, strengthen the status and leading role of enterprise innovation.

     “Specifically to the pharmaceutical industry, innovation-driven, transformation and upgrading is the only way for the development of China's pharmaceutical industry, guiding the integration of technological innovation elements into enterprises, and truly making enterprises the mainstay of technological innovation. As a pharmaceutical manufacturer, it is the first responsible person of drug quality, only By doing a good foundation study and narrowing the technological gap with developed countries, we can continuously improve the overall technical level, which is also a prerequisite for improving the quality of medicines. We continue to scientific and technological innovation, and ensure the quality of products through scientific and technological means. The whole process control from source to terminal strengthens the publicity of health education and common sense of medicine to ensure the safety of medication." Zhang Guimin said.

       Looking forward to the future of the enterprise during the "13th Five-Year Plan" period, Zhang Guimin said that "maintaining the advantages of chemical pharmaceuticals, vigorously developing Chinese medicine, and strengthening bio-pharmaceuticals" is the goal of Lunan Pharmaceutical Development. To implement the "healthy China" national strategy, deepening medical reform will be comprehensive. Pushing away, the core content also includes adhering to the emphasis on both Chinese and Western medicine, promoting the development of traditional Chinese medicine and ethnic medicine. "In the future, we will strive to develop Chinese medicine, strengthen chemical medicine, and expand biopharmaceuticals to continue technological innovation, create a century-old brand, and actively participate in international Competition will make a greater contribution to the realization of the 'Healthy China' goal." (Source: Xinhua Health)

上一页:How does a medical e-commerce guarantee the user experience in logistics?
下一页:Licensed pharmacist business specification (draft for comment) officially released

在线客服

在线客服
联系方式

全国热线:020-84128820